Clinical trials: Sexually Transmitted Diseases, Viral
HIV - Human Immunodeficiency Virus, Cognitive Symptoms
COMO: Cognition Study With HIV+ Patients (CTNPT 015)
The purpose of this study is to contribute evidence towards the potential to improve cognition in HIV+ individuals experiencing cognitive decline through personalized change in antiretroviral (ARV) medication.
- Trial name
- COMO (NCT02144688)
- Testing
- Change in antiretrovirals
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- Marie-Josée Brouillette
HIV Infections
Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection
The objective are to assess the nature and incidence of drug intolerance observed with a new antiretroviral triple therapy, Truvada® [0-0-1] + Isentress® 400 mg tablets [1-0-1], prescribed in a setting of the treatment of…
- Trial name
- NCT01114425
- Testing
- raltegravir (Isentress), Truvada®
- Where
- France
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux
HIV Infection, Bone Loss
Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)
With the increasing age of people living with HIV/AIDS, age-induced osteoporosis is likely to be compounded by HIV/AIDS and HAART-associated bone loss.
- Conditions
- HIV Infection, Bone Loss, Osteopenia, Osteoporosis
- Trial name
- BLIR-HIV (NCT01228318)
- Testing
- Zoledronic acid
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Emory University
Hiv
A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted
An Open-Label Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, given to a Population of Adults in Good General Health Who have Received 3 doses of 300µg BG505…
- Trial name
- NCT05983874
- Testing
- BG505 SOSIP.664 gp140 Vaccine, Adjuvanted (3M-052 AF plus alum) Dosage
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
HIV Infections
TMC114-C227: A Study to Evaluate the Effectiveness and Safety of TMC114 (Darunavir) With a Low Dose of Ritonavir as Monotherapy (no Other Anti-HIV Drugs Will be Given) in Patients Who Have Never Been Treated With Antiretrovirals (Anti-HIV Drugs) Previously
This is an open label study (no placebos are used; all patients will receive the true medication) to evaluate the effectiveness of TMC114/rtv in treatment naÃ-ve (never previously received anti-HIV drugs), HIV 1 infected patients.
- Trial name
- NCT00513513
- Testing
- TMC114 (darunavir) / ritonavir
- Volunteers
- 7 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Cervical Cancer, Human Papillomavirus Infection
Long Term Follow-up of HPV Vaccine in HIV (CTN 236)
The purpose of this extension study is to determine whether HPV antibody levels in HIV-positive girls and women will decline more rapidly and more significantly than in HIV-negative girls and women and if this decline is…
- Conditions
- Cervical Cancer, Human Papillomavirus Infection, Human Immunodeficiency Virus, Cervical Dysplasia
- Trial name
- NCT06915779
- Where
- 13 sites in Canada
- Volunteers
- 241 people
- Sponsor
- University of British Columbia
HIV, AIDS
Expansion to Interdisciplinary HIV Prevention in Women
This trial will pilot test intervention strategies to increase utilization of HIV testing and gain knowledge for designing a clinical trial to evaluate prevention strategies to reduce HIV sexual transmission in the general…
- Conditions
- HIV, AIDS, Fetal Alcohol Syndrome, Alcohol Related Neurodevelopmental Disorder
- Trial name
- NCT01994603
- Testing
- Opt-in or Opt-out testing, Focus Group
- Where
- 2 sites in United States, Russia
- Volunteers
- 41 people
- Sponsor
- University of Oklahoma
HIV Infections, Pregnancy
Maternal/Infant Peripartum NVP, Versus Infant Only Peripartum NVP, or Maternal LPV/r in Addition to Standard ZDV Prophylaxis for the Prevention of Perinatal (PMTCT) HIV in Thailand
The purpose of this study is to compare the efficacy of two doses of nevirapine (NVP) given only to the infants or lopinavir/ritonavir (LPV/r) from 28 weeks gestation with single dose (SD) NVP given to the mothers plus two doses…
- Trial name
- PHPT-5 (NCT00409591)
- Testing
- Maternal and infant nevirapine, Maternal lopinavir+ritonavir, zidovudine
- Where
- 43 sites in Thailand
- Volunteers
- 435 people
- Sponsor
- Institut de Recherche pour le Developpement
HIV Infections, Tuberculosis
Digital Health Promotion in Iringa, Tanzania
Increased health education has the potential to facilitate better use of health care services and to promote early treatment, thus it can strengthen the health care system, and ultimately reduce morbidity and mortality.
- Conditions
- HIV Infections, Tuberculosis, Cysticercosis, Tapeworm Pork
- Trial name
- NCT03808597
- Testing
- Digital health promotion intervention
- Where
- 6 sites in Tanzania
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of Oslo
Human Immunodeficiency Virus
Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (DRV/COB/FTC/TAF) is a coformulated STR, is the only protease inhibitor based STR, and is noted for its high tolerability3.
- Trial name
- SymITA (NCT04240210)
- Testing
- Symtuza
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Midland Research Group, Inc.
Human Immunodeficiency Virus
Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia
A 48-week, open label, non comparative prospective trial in stable chronic human immunodeficiency virus-infected patients having achieved complete virological suppression for more than 24 weeks (human immunodeficiency virus-1 RNA…
- Trial name
- NCT02652793
- Testing
- Boosted atazanavir, Lamivudine
- Where
- Spain
- Volunteers
- 31 people
- Sponsor
- Judit Pich
HIV/AIDS
Universal Coverage of Antiretroviral Treatment in Senegal
Senegal plans a rapid scale up of HIV treatment for all people living with HIV, regardless of cluster of differentiation 4 (CD4) count or viral suppression.
- Trial name
- NCT03880006
- Testing
- Case management
- Where
- 4 sites in Senegal
- Volunteers
- 596 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HIV Infections
Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV Infection
At the end of 2004 there were more than 40 million people infected worldwide with HIV, with an estimated 16,000 new infections every day (Joint United Nations Programme on HIV/AIDS [UNAIDS], 2004).
- Trial name
- NCT00386633
- Testing
- MVA-mBN32
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
HIV Infections
Long Term Follow-Up of HIV Infected Patients Who Have Previously Participated in HIV Clinical Trials
The purpose of this study is to monitor the progression of HIV infection and HIV-related disease processes in patients who have previously participated in HIV clinical trials.
- Trial name
- NCT00183287
- Volunteers
- 150 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety, Tolerance, Pharmacokinetic and Antiviral Study of Amdoxovir in Combination With Zidovudine in Adults With HIV
The purpose of this study is to determine the short term safety, tolerance, and antiviral effect of zidovudine (AZT) and amdoxovir (AMDX, DAPD) in combination, and whether the dosage for AZT can be reduced, potentially decreasing…
- Trial name
- NCT00432016
- Testing
- zidovudine, amdoxovir, pharmacokinetic sampling
- Where
- Argentina
- Volunteers
- 24 people
- Sponsor
- RFS Pharma, LLC
Human Immunodeficiency Virus, Alcohol-Related Disorders
Effectiveness & Implementation of a Behavioral Intervention for Adherence and Substance Use in HIV Care in South Africa
The purpose of this study is to test the effectiveness and implementation of a brief, integrated behavioral intervention for HIV medication adherence and substance use in the HIV care setting in South Africa.
- Conditions
- Human Immunodeficiency Virus, Alcohol-Related Disorders, Drug Use
- Trial name
- NCT03529409
- Testing
- Project Khanya
- Where
- 2 sites in United States, South Africa
- Volunteers
- 66 people
- Sponsor
- University of Maryland, College Park
Pneumonia, Pneumocystis Carinii, HIV Infections
An Open, Prospective, Multicenter Study of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia (PCP) and Serious Intolerance to Approved Therapies
To determine the safety and effectiveness of an investigational drug therapy (trimetrexate plus leucovorin calcium (TMTX / LCV)) in the treatment of Pneumocystis carinii pneumonia (PCP) in patients who have AIDS, are HIV…
- Trial name
- NCT00000714
- Testing
- Trimetrexate glucuronate, Leucovorin calcium
- Where
- 21 sites in United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Dementia
Modulation of Monocyte Activation by Atorvastatin in HIV Infection
Activated monocytes play a key role in the pathogenesis of HIV-associated neurocognitive disorders (HAND). Individuals with HAND have expanded populations of activated monocytes.
- Trial name
- NCT01263938
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Pennsylvania
HIV-1 Infection
A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents
The purpose of this study is to evaluate pharmacokinetics (what body does to medication), safety, tolerability, and efficacy (effectiveness) of darunavir with low-dose ritonavir (DRV/rtv) administered once daily, in combination…
- Trial name
- DIONE (NCT00915655)
- Testing
- darunavir, ritonavir, zidovudine
- Where
- 9 sites in United States, France and 4 more
- Volunteers
- 12 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV/AIDS, Medication Adherence
Centralized Off-Site Adherence Enhancement Program
Our proposal "Centralized Off-Site Adherence Enhancement Program" or "CARE" will develop and test an effective behavioral adherence intervention program for HIV patients with alcohol and/or substance abuse problems.
- Trial name
- CARE (NCT01409655)
- Testing
- cognitive-behavioral therapy
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of California, Los Angeles
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.